Home › Compare › YRIV vs MRK

YRIV vs MRK: Dividend Comparison 2026

YRIV yields 400000.00% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 YRIV wins by $5.011119029548644e+32M in total portfolio value
10 years
YRIV
YRIV
● Live price
400000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$5.011119029548644e+32M
Annual income
$500,865,583,351,836,840,000,000,000,000,000,000,000.00
Full YRIV calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — YRIV vs MRK

📍 YRIV pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodYRIVMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, YRIV + MRK cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
YRIV pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

YRIV
Annual income on $10K today (after 15% tax)
$34,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$425,735,745,849,061,300,000,000,000,000,000,000,000.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, YRIV beats the other by $425,735,745,849,061,300,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of YRIV + MRK for your $10,000?

YRIV: 50%MRK: 50%
100% MRK50/50100% YRIV
Portfolio after 10yr
$2.505559514774322e+32M
Annual income
$250,432,791,675,918,420,000,000,000,000,000,000,000.00/yr
Blended yield
99.95%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

YRIV
No analyst data
Altman Z
-0.4
Piotroski
2/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

YRIV buys
0
MRK buys
0
No recent congressional trades found for YRIV or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricYRIVMRK
Forward yield400000.00% ✓2.76%
Annual dividend / share$2.00$3.32 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7% ✓
Portfolio after 10y$5.011119029548644e+32M$56.8K ✓
Annual income after 10y$500,865,583,351,836,840,000,000,000,000,000,000,000.00 ✓$9,798.13
Total dividends collected$5.010957816668433e+32M$28.9K ✓
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: YRIV vs MRK ($10,000, DRIP)

YearYRIV PortfolioYRIV Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$40,010,700$40,000,000.00$11,206$366.19+$40.00M → YRIV
2$149,615,521,729$149,572,710,280.37$12,650$502.35+$149615.51M → YRIV
3$522,880,052,725,200$522,719,964,116,949.25$14,407$694.19+$522880052.71M → YRIV
4$1,707,862,989,289,045,000$1,707,303,507,632,628,700.00$16,585$967.82+$1707862989289.03M → YRIV
5$5,213,509,402,845,684,000,000$5,211,681,989,447,144,000,000.00$19,342$1,363.89+$5213509402845684.00M → YRIV
6$14,874,219,058,409,543,000,000,000$14,868,640,603,348,497,000,000,000.00$22,913$1,947.19+$14874219058409543680.00M → YRIV
7$39,661,196,234,050,755,000,000,000,000$39,645,280,819,658,260,000,000,000,000.00$27,662$2,823.89+$3.966119623405075e+22M → YRIV
8$98,838,436,350,327,300,000,000,000,000,000$98,795,998,870,356,880,000,000,000,000,000.00$34,159$4,173.35+$9.88384363503273e+25M → YRIV
9$230,205,236,474,344,900,000,000,000,000,000,000$230,099,479,347,450,050,000,000,000,000,000,000.00$43,337$6,308.80+$2.302052364743449e+29M → YRIV
10$501,111,902,954,864,400,000,000,000,000,000,000,000$500,865,583,351,836,840,000,000,000,000,000,000,000.00$56,776$9,798.13+$5.011119029548644e+32M → YRIV

YRIV vs MRK: Complete Analysis 2026

YRIV — Stock

Yangtze River Port and Logistics Limited, through its subsidiary, Wuhan Yangtze River Newport Logistics Co., Ltd., primarily engages in the real estate and infrastructural development business in the People's Republic of China. It operates Wuhan Yangtze River Newport Logistics Center, a port logistics center located in Wuhan Newport Yangluo Port, Hubei Province of China. The company was formerly known as Yangtze River Development Limited and changed its name to Yangtze River Port and Logistics Limited in February 2018. Yangtze River Port and Logistics Limited is headquartered in New York, New York.

Full YRIV Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this YRIV vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

YRIV vs SCHDYRIV vs JEPIYRIV vs OYRIV vs KOYRIV vs MAINYRIV vs JNJYRIV vs ABBVYRIV vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.